Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Physiomics ( (GB:PYC) ) has provided an update.
Physiomics plc, a mathematical modelling and data science company serving the biopharmaceutical sector, uses bespoke models and bioinformatics to de-risk drug development decisions and optimise study design across the R&D lifecycle. Its Virtual Tumour platform has supported more than 140 commercial projects and over 125 drug targets, underpinning its role as a specialised partner to major industry players.
The company announced that shareholders approved all resolutions at a requisitioned general meeting, leading to the appointment of Michael Whitlow as executive director, and Nicholas Tulloch as non-executive chair, alongside non-executive director Ian Bagnall, while four existing board members, including chair Dr Tim Corn and director-CEO Dr Peter Sargent, were removed. Sargent will remain as non-board CEO until 29 May 2026 to support an orderly transition, while the incoming directors bring capital markets, investment and operational experience, with Whitlow and Bagnall together controlling about 15.7% of the company’s shares, signalling a significant shift in governance and strategic influence.
Spark’s Take on PYC Stock
According to Spark, TipRanks’ AI Analyst, PYC is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and persistent cash burn), partially offset by a low-leverage balance sheet and some improvement in price trend. Valuation is constrained by negative earnings and lack of dividend support.
To see Spark’s full report on PYC stock, click here.
More about Physiomics
Physiomics plc is a UK-based mathematical modelling, data science and biostatistics specialist focused on supporting the development of new therapeutics and personalised medicine solutions for biotech and pharma clients. Leveraging proprietary computational tools such as its Virtual Tumour technology, the company helps streamline drug development across discovery, pre-clinical and clinical stages for partners including Merck KGaA, Astellas and Cancer Research UK.
Average Trading Volume: 8,273,103
Technical Sentiment Signal: Sell
Current Market Cap: £2.27M
Find detailed analytics on PYC stock on TipRanks’ Stock Analysis page.